NCT06460038View on ClinicalTrials.gov

Tenapanor in Synucleinopathy-Related Constipation

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

SynucleinopathyParkinson's Disease

Interventions

DRUG

Tenapanor

Inhibitor of NHE3

DRUG

Placebo

Placebo drug

Trial Locations (1)

50701

RECRUITING

Cedar Valley Digestive Health Center, Waterloo

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Ardelyx

INDUSTRY

lead

Cedar Valley Digestive Health Center

OTHER